HTL 9936

Drug Profile

HTL 9936

Alternative Names: HTL-0009936; HTL-9936

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Class Antidementias; Nootropics; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 01 Aug 2016 Heptares Therapeutics completes a phase I trial in Cognition disorders (In volunteers) in United Kingdom (NCT02710188)
  • 17 Apr 2016 Biomarkers information updated
  • 07 Apr 2016 HTL 9936 licensed to Allergan Pharmaceuticals worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top